Fedratinib for disease-related splenomegaly and symptoms in myelofibrosis [ID1501]
In development [GID-TA10406] Expected publication date: 25 August 2021
Search results
596 results
-
-
Anakinra for treating active Stills disease [ID1463]
In development [GID-TA10392] Expected publication date: 31 March 2021
-
Esketamine for treatment-resistant depression (ID1414)
In development [GID-TA10371] Expected publication date: TBC
-
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection [ID3835]
In development [GID-TA10756] Expected publication date: 22 September 2021
-
Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome [ID1405]
In development [GID-TA10305] Expected publication date: 31 March 2021
-
Fenfluramine for treating Dravet syndrome [ID1109]
In development [GID-TA10373] Expected publication date: 26 May 2021
-
Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID968]
In development [GID-TA10334] Expected publication date: TBC
-
Pembrolizumab with lenvatinib for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3809]
In development [GID-TA10697] Expected publication date: TBC
-
Mexiletine for treating myotonia in adults with non-dystrophic myotonic disorders ID1488
In development [GID-TA10432] Expected publication date: TBC
-
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy [ID2727]
In development [GID-TA10674] Expected publication date: TBC
-
Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy [ID1602]
In development [GID-TA10524] Expected publication date: TBC
-
Olaparib for previously treated, hormone-relapsed metastatic prostate cancer with homologous recombination repair gene mutations [ID1640]
In development [GID-TA10584] Expected publication date: TBC
-
Pembrolizumab with pemetrexed and platinum-based chemotherapy for previously TKI-treated EGFR-positive metastatic non-squamous non-small-cell lung cancer [ID3873]
In development [GID-TA10766] Expected publication date: TBC
-
Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]
In development [GID-HST10004] Expected publication date: TBC
-
Eteplirsen for treating Duchenne muscular dystrophy [ID1003]
In development [GID-HST10007] Expected publication date: TBC
-
Xpert MTB/RIF assay for the detection of active pulmonary tuberculosis and multi-drug resistant tuberculosis
In development [GID-DT9] Expected publication date: TBC
-
KRAS mutation testing of tumours in adults with metastatic colorectal cancer (discontinued)
In development [GID-DT14] Expected publication date: TBC
-
Multiple myeloma and related disorders - Freelite assays (and alternative technologies identified during scoping) for diagnosis in primary care
In development [GID-DT28] Expected publication date: TBC
-
Cutting blocks for total knee arthroplasty
In development [GID-IP1112] Expected publication date: TBC
-
Implantable Vagus Nerve Stimulator in Heart Failure
In development [GID-IP1145] Expected publication date: TBC
-
Autologous unmanipulated peripheral blood stem cell therapy for multiple sclerosis
In development [GID-IP1151] Expected publication date: TBC
-
Extra corporeal membrane oxygenation for acute heart failure in children
In development [GID-IP1153] Expected publication date: TBC
-
Degradable surgical implant
In development [GID-IP1197] Expected publication date: TBC
-
MRI guided focussed ultrasound for chronic pain
In development [GID-IP1043] Expected publication date: TBC
-
Ex utero intrapartum therapy for fetal obstruction
In development [GID-IP1156] Expected publication date: TBC
-
Peroral endoscopic myotomy (POEM) for achalasia
In development [GID-IP1229] Expected publication date: TBC
-
Spineform Hemibridge endoscopic vertebral stapling to reduce curvature in the growing scoliotic spine in children
In development [GID-IP1170] Expected publication date: TBC
-
Intravaginal sling for stress urinary incontinence
In development [GID-IP267] Expected publication date: TBC
-
Electrochemotherapy for the treatment of malignant melanoma
In development [GID-IP1041] Expected publication date: TBC
-
Durvalumab with tremelimumab for treating squamous cell head and neck cancer after platinum-based chemotherapy [ID1144]
In development [GID-TA10474] Expected publication date: TBC
-
Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861]
In development [GID-TA10780] Expected publication date: TBC
-
Idebenone for treating Duchenne muscular dystrophy ID1092
In development [GID-TA10310] Expected publication date: TBC
-
Nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma ID1610
In development [GID-TA10499] Expected publication date: TBC
-
Ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia [ID1548]
In development [GID-TA10416] Expected publication date: TBC
-
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]
In development [GID-TA10555] Expected publication date: TBC
-
Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma ID1305
In development [GID-TA10244] Expected publication date: TBC
-
Olaparib for maintenance treatment of recurrent, platinum-sensitive ovarian, fallopian tube and peritoneal cancer that has responded to platinum-based chemotherapy (CDF review of TA620) [ID3788]
In development [GID-TA10712] Expected publication date: TBC
-
Vericiguat for treating chronic heart failure with reduced ejection fraction [ID2731]
In development [GID-TA10595] Expected publication date: TBC
-
Durvalumab in combination for untreated extensive stage small-cell lung cancer [ID1618]
In development [GID-TA10493] Expected publication date: TBC
-
Glasdegib with chemotherapy for untreated acute myeloid leukaemia [ID1334]
In development [GID-TA10314] Expected publication date: TBC
-
Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer ID1357
In development [GID-TA10322] Expected publication date: TBC
-
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]
In development [GID-TA10467] Expected publication date: TBC
-
Pembrolizumab for advanced, unresectable or metastatic urothelial cancer (CDF review of TA522) [ID1634]
In development [GID-TA10710] Expected publication date: TBC
-
Nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation [ID1582]
In development [GID-TA10495] Expected publication date: 18 August 2021
-
Galcanezumab for preventing cluster headache [ID1212]
In development [GID-TA10425] Expected publication date: 24 February 2021
-
Blinatumomab for treating Philadelphia-chromosome-positive relapsed or refractory acute lymphoblastic leukaemia [ID1008]
In development [GID-TA10119] Expected publication date: TBC
-
Constipation (opioid induced) - lubiprostone [ID646]
In development [GID-TAG367] Expected publication date: 01 October 2014
-
Omalizumab for treating chronic rhinosinusitis with nasal polyps [ID1650]
In development [GID-TA10558] Expected publication date: TBC
-
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]
In development [GID-TA10405] Expected publication date: TBC
-
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]
In development [GID-TA10667] Expected publication date: TBC